Citations

Clear

3138 citation(s) found for "Smith, AM".

Heartburn As a Marker of the Success of Acid Suppression Therapy in Chronic Cough.
Badri, Huda , Mangi, Muhammad Asif , Tangaroonsanti, Anupong, DeVault, Kenneth R. , Lee, A. S., Satia, Imran , Bansal, Vikas , Houghton, Lesley A. , Smith, John A.

Mayo Clinic

No container title available | September 15, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-886153/v1 Get It

Abstract Purpose: Gastro-oesophageal reflux disease (GORD) is commonly thought to play an important role in chronic cough and patients are often empirically treated with acid suppression therapy. We sought to investigate the response rate to acid suppression treatment in patients with and without heartburn attending two specialist cough clinics. Methods: A retrospective review of 558 consecutive patients referred to two specialist cough clinics was performed (UK and US). Patients who were treated with acid suppression were included and their documented response to treatment collected. Binary logistic regression was used to ascertain the value of reported heartburn in predicting the response of chronic cough to acid suppression therapy. Results: Of 558 consecutive referrals, 238 patients were excluded due to missing data or cough duration of <8weeks. The remaining 320 patients were predominantly female (76%), mean age 61yrs (±13), 96.8% non-smokers, with chronic cough for 36 (18-117) months. Of 72 patients with heartburn, 20 (28%) noted improvement in their cough with acid suppression, whereas of 248 without heartburn, only 35 (14%) responded. Patients reporting heartburn were 2.7 (95% C.I. 1.3-5.6) times more likely to respond to acid suppression therapy (p=0.007).Conclusion: In specialist cough clinics, few patients report a response of their chronic cough to acid suppression therapy. Nonetheless, heartburn is a useful predictor substantially increasing the likelihood of benefit.
Successful outcomes with transplanting kidneys from deceased donors with acute kidney injuryon temporary renal replacement therapy
Budhiraja, Pooja , Heilman, Raymond L. , Ryan, Margaret , Khamash, Hasan , Kodali, Lavanya , Moss, Adyr A. , Mathur, Amit K. , Reddy, Kunam S. , Jadlowiec, Caroline , Ryan, Margaret S, Khamash, Hasan A, Mathur, Amit , Budhiraja, Pooja , Jadlowiec, Caroline C. , Smith, Maxwell L.

Mayo Clinic

Clinical Transplantation | September 13, 2021 | Volume: 35 | Issue: 12 | Pages: No page available

10.1111/ctr.14465 | PMID 34514643 Get It

AbstractBackground and objectivesWe aimed to determine outcomes with transplanting kidneys from deceased donors with severe acute kidney injury requiring acute renal replacement therapy (RRT).Materials and methodsA total of 172 recipients received a kidney from donors with acute kidney injury stage 3 (AKIN3) requiring RRT. We compared the study group to 528 recipients who received a kidney from donors with AKIN stage 3 not on RRT and 463 recipients who received < 85% Kidney Donor Profile Index (KDPI) AKIN stage 0 kidney.ResultsThe study group donors were younger compared to the 2 control groups. Despite higher DGF in the study group, the length of hospital stay and acute rejection were similar. Death censored graft survival (96% AKIN3‐RRT vs. 97%AKIN3 no RRT vs. 96% KDPI < 85% AKIN0,P = 0.26) and patient survival with functioning graft at 1 year (95% across all groups,P = 0.402) were similar. The estimated glomerular filtration rate were similar across the 3 groups after first month. Interstitial fibrosis and tubular atrophy score ≥ 2 on protocol biopsy at time 0, 4 and 12 months were similar. Primary nonfunction was rare and associated with high KDPI.ConclusionsTransplanting selected kidneys from deceased donors with AKIN3 requiring RRT is safe and has good outcomes.
Latent Factor Structure of Outcome Measures Used in the HABIT® Mild Cognitive Impairment Intervention Programs
DeFeis, Brittany , Ying, Gelan , Kurasz, Andrea M. , Wit, Liselotte De , Amofa, Priscilla , Chandler, Melanie , Shandera‐Ochsner, Anne L., Phatak, Vaishali , Locke, Dona, Shandera-Ochsner, Anne, De Wit, Liselotte , Locke, Dona E.C. , Smith, Glenn E.

Mayo Clinic

Journal of Alzheimer's Disease | September 10, 2021 | Volume: 84 | Issue: 1 | Pages: 193-205

10.3233/jad-210582 | PMID 34511501 Get It

Background: In Alzheimer’s disease and related disorders (ADRD) research, common outcome measures include cognitive and functional impairment, as well as persons with mild cognitive impairment (pwMCI) and care partner self-reported mood and quality of life. Studies commonly analyze these measures separately, which potentially leads to issues of multiple comparisons and/or multicollinearity among measures while ignoring the latent constructs they may be measuring. Objective: This study sought to examine the latent factor structure of a battery of 12-13 measures of domains mentioned above, used in a multicomponent behavioral intervention (The HABIT® program) for pwMCI and their partners. Methods: Exploratory factor analysis (EFA) involved 214 pwMCI-partner pairs. Subsequent Confirmatory factor analyses (CFA) used 730 pairs in both pre- and post-intervention conditions. Results: EFA generated a three-factor model. Factors could be characterized as partner adjustment (29.9%), pwMCI adjustment (18.1%), and pwMCI impairment (12.8%). The subsequent CFA confirmed our findings, and the goodness-of-fit for this model was adequate in both the pre- (CFI = 0.937; RMSEA = 0.057, p = 0.089) and post-intervention (CFI = 0.942; RMSEA = 0.051, p = 0.430) groups. Conclusion: Results demonstrated a stable factor structure across cohorts and intervention conditions suggesting that three broad factors may provide a straightforward and meaningful model to assess intervention outcome, at least during the MCI phase of ADRD.
Assessing the rate, natural history, and treatment trends of intracranial aneurysms in patients with intracranial dural arteriovenous fistulas: a Consortium for Dural Arteriovenous Fistula Outcomes Research (CONDOR) investigation
Abecassis, Isaac Josh, Meyer, R. Michael, Levitt, Michael R. , Sheehan, Jason P. , Gross, Bradley A. , Lockerman, Ashley, Brinjikji, Waleed , Starke, Robert M. , Chen, Stephanie H. , Potgieser, Adriaan R. E., Dijk, J. Marc C. van , Durnford, Andrew , Bulters, Diederik , Satomi, Junichiro, Tada, Yoshiteru , Kwasnicki, Amanda , Amin‐Hanjani, Sepideh , Alaraj, Ali , Hayakawa, M. , Derdeyn, Colin P. , Winkler, Ethan A. , Abla, Adib A. , Guniganti, Ridhima , Kansagra, Akash P. , Zipfel, Gregory J. , Kim, Louis J. , _, _, _, _, Piccirillo, Jay F. , Vine, Roanna , Cloft, Harry J. , Kallmes, David F. , Pollock, Bruce E. , Link, Michael J., Patibandla, Mohana Rao, Buell, Thomas J. , Paisan, Gabriella, Kelly, Cory , Duffill, Jonathan, Ditchfield, Adam, Millar, John S. , Macdonald, Jason, Polifka, Adam , Laurent, Dimitri , Lunsford, L. Dade , Jankowitz, Brian T. , Guerrero, Waldo R. , McGruder, Allen, Charbel, Fady T. , Aletich, Victor , Rose‐Finnell, Linda, Peterson, Eric C. , Yavagal, Dileep R. , Sur, Samir , Kanematsu, Yasuhisa , Kinouchi, T. , Korai, Masaaki , Yamaguchi, Izumi , Yamamoto, Yuki , Lawton, Michael T. , Rutkowski, Martin J. , Aziz‐Sultan, Mohammad Ali , Patel, Nirav , Frerichs, Kai U., Levitt, Michael R , Amin-Hanjani, Sepideh , Alaraj, Ali , van DijK, J Marc C , Abla, Adib , Bulters, Diederik O , Derdeyn, Colin P , Chen, Ching‐Jen , Gross, Bradley , Fox, W Christopher , Lanzino, Giuseppe , Samaniego, Edgar A , Lai, Pui Man Rosalind , Du, Rose , Kim, Louis J. , _, _, _, _, Raman, Hari S. , Lipsey, Kim L. , Giordan, Enrico , Link, Michael J. , Ding, Dale , Hoh, Brian L. , Smith, Jessica , Ortega-Gutierrez, Santiago , Hasan, David , Roa, Jorge A. , Rossen, James D. , Yamamoto, Nobuaki , Phelps, Ryan

Mayo Clinic

Journal of Neurosurgery | September 10, 2021 | Volume: 136 | Issue: 4 | Pages: 971-980

10.3171/2021.1.jns202861 | PMID 34507300 Get It

OBJECTIVE There is a reported elevated risk of cerebral aneurysms in patients with intracranial dural arteriovenous fistulas (dAVFs). However, the natural history, rate of spontaneous regression, and ideal treatment regimen are not well characterized. In this study, the authors aimed to describe the characteristics of patients with dAVFs and intracranial aneurysms and propose a classification system. METHODS The Consortium for Dural Arteriovenous Fistula Outcomes Research (CONDOR) database from 12 centers was retrospectively reviewed. Analysis was performed to compare dAVF patients with (dAVF+ cohort) and without (dAVF-only cohort) concomitant aneurysm. Aneurysms were categorized based on location as a dAVF flow-related aneurysm (FRA) or a dAVF non–flow-related aneurysm (NFRA), with further classification as extra- or intradural. Patients with traumatic pseudoaneurysms or aneurysms with associated arteriovenous malformations were excluded from the analysis. Patient demographics, dAVF anatomical information, aneurysm information, and follow-up data were collected. RESULTS Of the 1077 patients, 1043 were eligible for inclusion, comprising 978 (93.8%) and 65 (6.2%) in the dAVF-only and dAVF+ cohorts, respectively. There were 96 aneurysms in the dAVF+ cohort; 10 patients (1%) harbored 12 FRAs, and 55 patients (5.3%) harbored 84 NFRAs. Dural AVF+ patients had higher rates of smoking (59.3% vs 35.2%, p < 0.001) and illicit drug use (5.8% vs 1.5%, p = 0.02). Sixteen dAVF+ patients (24.6%) presented with aneurysm rupture, which represented 16.7% of the total aneurysms. One patient (1.5%) had aneurysm rupture during follow-up. Patients with dAVF+ were more likely to have a dAVF located in nonconventional locations, less likely to have arterial supply to the dAVF from external carotid artery branches, and more likely to have supply from pial branches. Rates of cortical venous drainage and Borden type distributions were comparable between cohorts. A minority (12.5%) of aneurysms were FRAs. The majority of the aneurysms underwent treatment via either endovascular (36.5%) or microsurgical (15.6%) technique. A small proportion of aneurysms managed conservatively either with or without dAVF treatment spontaneously regressed (6.2%). CONCLUSIONS Patients with dAVF have a similar risk of harboring a concomitant intracranial aneurysm unrelated to the dAVF (5.3%) compared with the general population (approximately 2%–5%) and a rare risk (0.9%) of harboring an FRA. Only 50% of FRAs are intradural. Dural AVF+ patients have differences in dAVF angioarchitecture. A subset of dAVF+ patients harbor FRAs that may regress after dAVF treatment.
Dural arteriovenous fistulas without cortical venous drainage: presentation, treatment, and outcomes
Samaniego, Edgar A., Roa, Jorge A., Hayakawa, Minako, Chen, Ching-Jen, Sheehan, Jason P., Kim, Louis J., Abecassis, Isaac Josh, Levitt, Michael R., Guniganti, Ridhima, Kansagra, Akash P., Lanzino, Giuseppe, Giordan, Enrico, Brinjikji, Waleed, Bulters, Diederik, Durnford, Andrew, Fox, W. Christopher, Polifka, Adam J., Gross, Bradley A., Amin-Hanjani, Sepideh, Alaraj, Ali, Kwasnicki, Amanda, Starke, Robert M., Sur, Samir, Dijk, J. Marc C. van, Potgieser, Adriaan R. E., Satomi, Junichiro, Tada, Yoshiteru, Abla, Adib, Winkler, Ethan, Du, Rose, Lai, Pui Man Rosalind, Zipfel, Gregory J., Derdeyn, Colin P., _, _, _, _, Zipfel, Gregory J., Kansagra, Akash P., Guniganti, Ridhima, Piccirillo, Jay F., Raman, Hari, Lipsey, Kim, Lanzino, Giuseppe, Giordan, Enrico, Brinjikji, Waleed, Vine, Roanna, Cloft, Harry J., Kallmes, David F., Pollock, Bruce E., Link, Michael J., Sheehan, Jason, Chen, Ching-Jen, Patibandla, Mohana Rao, Ding, Dale, Buell, Thomas, Paisan, Gabriella, Kim, Louis J., Levitt, Michael R., Abecassis, Isaac Josh, Meyer, R. Michael, Kelly, Cory, Bulters, Diederik, Durnford, Andrew, Duffill, Jonathan, Ditchfield, Adam, Millar, John, Macdonald, Jason, Fox, W. Christopher, Polifka, Adam J., Laurent, Dimitri, Hoh, Brian, Smith, Jessica, Lockerman, Ashley, Gross, Bradley A., Lunsford, L. Dade, Jankowitz, Brian T., Hayakawa, Minako, Derdeyn, Colin P., Samaniego, Edgar A., Gutierrez, Santiago Ortega, Hasan, David, Roa, Jorge A., Rossen, James, Guerrero, Waldo, McGruder, Allen, Amin-Hanjani, Sepideh, Alaraj, Ali, Kwasnicki, Amanda, Charbel, Fady T., Aletich, Victor A., Rose-Finnell, Linda, Dijk, J. Marc C. van, Potgieser, Adriaan R. E., Starke, Robert M., Peterson, Eric C., Yavagal, Dileep R., Sur, Samir, Chen, Stephanie H., Satomi, Junichiro, Tada, Yoshiteru, Kanematsu, Yasuhisa, Yamamoto, Nobuaki, Kinouchi, Tomoya, Korai, Masaaki, Yamaguchi, Izumi, Yamamoto, Yuki, Abla, Adib, Winkler, Ethan, Phelps, Ryan R. L., Lawton, Michael, Rutkowski, Martin, Du, Rose, Lai, Pui Man Rosalind, Aziz-Sultan, M. Ali, Patel, Nirav, Frerichs, Kai U., Derdeyn, Colin P. , Amin‐Hanjani, Sepideh , Bulters, Diederik , Aziz‐Sultan, Mohammad Ali , Levitt, Michael R. , Hayakawa, M. , Alaraj, Ali , Dijk, J. Marc C. van , Abla, Adib A. , Korai, Masaaki , Lai, Pui Man Rosalind , Levitt, Michael R , Amin-Hanjani, Sepideh , Alaraj, Ali , van DijK, J Marc C , Abla, Adib , Lai, Rosalind , Bulters, Diederik O , Derdeyn, Colin P , Samaniego, Edgar A., Roa, Jorge A., Hayakawa, Minako, Chen, Ching-Jen, Sheehan, Jason P., Kim, Louis J., Abecassis, Isaac Josh, Levitt, Michael R., Guniganti, Ridhima, Kansagra, Akash P., Lanzino, Giuseppe, Giordan, Enrico, Brinjikji, Waleed, Durnford, Andrew, Fox, W. Christopher, Polifka, Adam J., Gross, Bradley A., Kwasnicki, Amanda, Starke, Robert M., Sur, Samir, Dijk, J. Marc C. van, Potgieser, Adriaan R. E., Satomi, Junichiro, Tada, Yoshiteru, Winkler, Ethan, Du, Rose, Lai, Pui Man Rosalind, Zipfel, Gregory J., _, _, _, _, Zipfel, Gregory J., Kansagra, Akash P., Guniganti, Ridhima, Piccirillo, Jay F., Raman, Hari, Lipsey, Kim, Lanzino, Giuseppe, Giordan, Enrico, Brinjikji, Waleed, Vine, Roanna, Cloft, Harry J., Kallmes, David F., Pollock, Bruce E., Link, Michael J., Sheehan, Jason, Chen, Ching-Jen, Patibandla, Mohana Rao, Ding, Dale, Buell, Thomas, Paisan, Gabriella, Kim, Louis J., Abecassis, Isaac Josh, Meyer, R. Michael, Kelly, Cory, Bulters, Diederik, Durnford, Andrew, Duffill, Jonathan, Ditchfield, Adam, Millar, John, Macdonald, Jason, Fox, W. Christopher, Polifka, Adam J., Laurent, Dimitri, Hoh, Brian, Smith, Jessica, Lockerman, Ashley, Gross, Bradley A., Lunsford, L. Dade, Jankowitz, Brian T., Hayakawa, Minako, Derdeyn, Colin P., Samaniego, Edgar A., Gutierrez, Santiago Ortega, Hasan, David, Roa, Jorge A., Rossen, James, Guerrero, Waldo, McGruder, Allen, Amin-Hanjani, Sepideh, Alaraj, Ali, Kwasnicki, Amanda, Charbel, Fady T., Aletich, Victor A., Rose-Finnell, Linda, Dijk, J. Marc C. van, Potgieser, Adriaan R. E., Starke, Robert M., Peterson, Eric C., Yavagal, Dileep R., Sur, Samir, Chen, Stephanie H., Satomi, Junichiro, Tada, Yoshiteru, Kanematsu, Yasuhisa, Yamamoto, Nobuaki, Kinouchi, Tomoya, Yamaguchi, Izumi, Yamamoto, Yuki, Abla, Adib, Winkler, Ethan, Phelps, Ryan R. L., Lawton, Michael, Rutkowski, Martin, Du, Rose, Lai, Pui Man Rosalind, Patel, Nirav, Frerichs, Kai U.

Mayo Clinic

Journal of Neurosurgery | September 10, 2021 | Volume: 136 | Issue: 4 | Pages: 942-950

10.3171/2021.1.jns202825 | PMID 34507278 Get It

OBJECTIVE Current evidence suggests that intracranial dural arteriovenous fistulas (dAVFs) without cortical venous drainage (CVD) have a benign clinical course. However, no large study has evaluated the safety and efficacy of current treatments and their impact over the natural history of dAVFs without CVD. METHODS The authors conducted an analysis of the retrospectively collected multicenter Consortium for Dural Arteriovenous Fistula Outcomes Research (CONDOR) database. Patient demographics and presenting symptoms, angiographic features of the dAVFs, and treatment outcomes of patients with Borden type I dAVFs were reviewed. Clinical and radiological follow-up information was assessed to determine rates of new intracranial hemorrhage (ICH) or nonhemorrhagic neurological deficit (NHND), worsening of venous hyperdynamic symptoms (VHSs), angiographic recurrence, and progression or spontaneous regression of dAVFs over time. RESULTS A total of 342 patients/Borden type I dAVFs were identified. The mean patient age was 58.1 ± 15.6 years, and 62% were women. The mean follow-up time was 37.7 ± 54.3 months. Of 230 (67.3%) treated dAVFs, 178 (77%) underwent mainly endovascular embolization, 11 (4.7%) radiosurgery alone, and 4 (1.7%) open surgery as the primary modality. After the first embolization, most dAVFs (47.2%) achieved only partial reduction in early venous filling. Multiple complementary interventions increased complete obliteration rates from 37.9% after first embolization to 46.7% after two or more embolizations, and 55.2% after combined radiosurgery and open surgery. Immediate postprocedural complications occurred in 35 dAVFs (15.2%) and 6 (2.6%) with permanent sequelae. Of 127 completely obliterated dAVFs by any therapeutic modality, 2 (1.6%) showed angiographic recurrence/recanalization at a mean of 34.2 months after treatment. Progression to Borden-Shucart type II or III was documented in 2.2% of patients and subsequent development of a new dAVF in 1.6%. Partial spontaneous regression was found in 22 (21.4%) of 103 nontreated dAVFs. Multivariate Cox regression analysis demonstrated that older age, NHND, or severe venous-hyperdynamic symptoms at presentation and infratentorial location were associated with worse prognosis. Kaplan-Meier curves showed no significant difference for stable/improved symptoms survival probability in treated versus nontreated dAVFs. However, estimated survival times showed better trends for treated dAVFs compared with nontreated dAVFs (288.1 months vs 151.1 months, log-rank p = 0.28). This difference was statistically significant for treated dAVFs with 100% occlusion (394 months, log-rank p < 0.001). CONCLUSIONS Current therapeutic modalities for management of dAVFs without CVD may provide better symptom control when complete angiographic occlusion is achieved.
Intervention for unruptured high-grade intracranial dural arteriovenous fistulas: a multicenter study
Chen, Ching-Jen, Buell, Thomas J., Ding, Dale, Guniganti, Ridhima, Kansagra, Akash P., Lanzino, Giuseppe, Giordan, Enrico, Kim, Louis J., Levitt, Michael R., Abecassis, Isaac Josh, Bulters, Diederik, Durnford, Andrew, Fox, W. Christopher, Polifka, Adam J., Gross, Bradley A., Hayakawa, Minako, Derdeyn, Colin P., Samaniego, Edgar A., Amin-Hanjani, Sepideh, Alaraj, Ali, Kwasnicki, Amanda, Dijk, J. Marc C. van, Potgieser, Adriaan R. E., Starke, Robert M., Sur, Samir, Satomi, Junichiro, Tada, Yoshiteru, Abla, Adib A., Winkler, Ethan A., Du, Rose, Lai, Pui Man Rosalind, Zipfel, Gregory J., Sheehan, Jason P., _, _, _, _, Zipfel, Gregory J., Kansagra, Akash P., Guniganti, Ridhima, Piccirillo, Jay F., Raman, Hari, Lipsey, Kim, Lanzino, Giuseppe, Giordan, Enrico, Brinjikji, Waleed, Vine, Roanna, Cloft, Harry J., Kallmes, David F., Pollock, Bruce E., Link, Michael J., Sheehan, Jason, Chen, Ching-Jen, Patibandla, Mohana Rao, Ding, Dale, Buell, Thomas, Paisan, Gabriella, Kim, Louis J., Levitt, Michael R., Abecassis, Isaac Josh, Meyer, R. Michael, Kelly, Cory, Bulters, Diederik, Durnford, Andrew, Duffill, Jonathan, Ditchfield, Adam, Millar, John, Macdonald, Jason, Fox, W. Christopher, Polifka, Adam J., Laurent, Dimitri, Hoh, Brian, Smith, Jessica, Lockerman, Ashley, Gross, Bradley A., Lunsford, L. Dade, Jankowitz, Brian T., Hayakawa, Minako, Derdeyn, Colin P., Samaniego, Edgar A., Gutierrez, Santiago Ortega, Hasan, David, Roa, Jorge A., Rossen, James, Guerrero, Waldo, McGruder, Allen, Amin-Hanjani, Sepideh, Alaraj, Ali, Kwasnicki, Amanda, Charbel, Fady T., Aletich, Victor A., Rose-Finnell, Linda, Dijk, J. Marc C. van, Potgieser, Adriaan R. E., Starke, Robert M., Peterson, Eric C., Yavagal, Dileep R., Sur, Samir, Chen, Stephanie H., Satomi, Junichiro, Tada, Yoshiteru, Kanematsu, Yasuhisa, Yamamoto, Nobuaki, Kinouchi, Tomoya, Korai, Masaaki, Yamaguchi, Izumi, Yamamoto, Yuki, Abla, Adib, Winkler, Ethan, Phelps, Ryan R. L., Lawton, Michael, Rutkowski, Martin, Du, Rose, Lai, Pui Man Rosalind, Aziz-Sultan, M. Ali, Patel, Nirav, Frerichs, Kai U., Derdeyn, Colin P. , Amin‐Hanjani, Sepideh , Bulters, Diederik , Aziz‐Sultan, Mohammad Ali , Giordan, Enrico , Levitt, Michael R. , Ding, Dale , Hayakawa, M. , Alaraj, Ali , Dijk, J. Marc C. van , Abla, Adib A. , Korai, Masaaki , Lai, Pui Man Rosalind , Levitt, Michael R , Ding, Dale , Amin-Hanjani, Sepideh , Alaraj, Ali , van DijK, J Marc C , Abla, Adib , Lai, Rosalind , Bulters, Diederik O , Derdeyn, Colin P , Chen, Ching-Jen, Buell, Thomas J., Ding, Dale, Guniganti, Ridhima, Kansagra, Akash P., Lanzino, Giuseppe, Kim, Louis J., Abecassis, Isaac Josh, Bulters, Diederik, Durnford, Andrew, Fox, W. Christopher, Polifka, Adam J., Gross, Bradley A., Hayakawa, Minako, Derdeyn, Colin P., Samaniego, Edgar A., Alaraj, Ali, Kwasnicki, Amanda, Dijk, J. Marc C. van, Potgieser, Adriaan R. E., Starke, Robert M., Sur, Samir, Satomi, Junichiro, Tada, Yoshiteru, Abla, Adib A., Winkler, Ethan A., Du, Rose, Lai, Pui Man Rosalind, Zipfel, Gregory J., Sheehan, Jason P., _, _, _, _, Zipfel, Gregory J., Kansagra, Akash P., Guniganti, Ridhima, Piccirillo, Jay F., Raman, Hari, Lipsey, Kim, Lanzino, Giuseppe, Giordan, Enrico, Brinjikji, Waleed, Vine, Roanna, Cloft, Harry J., Kallmes, David F., Pollock, Bruce E., Link, Michael J., Sheehan, Jason, Chen, Ching-Jen, Patibandla, Mohana Rao, Ding, Dale, Buell, Thomas, Paisan, Gabriella, Kim, Louis J., Levitt, Michael R., Abecassis, Isaac Josh, Meyer, R. Michael, Kelly, Cory, Durnford, Andrew, Duffill, Jonathan, Ditchfield, Adam, Millar, John, Macdonald, Jason, Fox, W. Christopher, Polifka, Adam J., Laurent, Dimitri, Hoh, Brian, Smith, Jessica, Lockerman, Ashley, Gross, Bradley A., Lunsford, L. Dade, Jankowitz, Brian T., Hayakawa, Minako, Samaniego, Edgar A., Gutierrez, Santiago Ortega, Hasan, David, Roa, Jorge A., Rossen, James, Guerrero, Waldo, McGruder, Allen, Amin-Hanjani, Sepideh, Kwasnicki, Amanda, Charbel, Fady T., Aletich, Victor A., Rose-Finnell, Linda, Dijk, J. Marc C. van, Potgieser, Adriaan R. E., Starke, Robert M., Peterson, Eric C., Yavagal, Dileep R., Sur, Samir, Chen, Stephanie H., Satomi, Junichiro, Tada, Yoshiteru, Kanematsu, Yasuhisa, Yamamoto, Nobuaki, Kinouchi, Tomoya, Yamaguchi, Izumi, Yamamoto, Yuki, Abla, Adib, Winkler, Ethan, Phelps, Ryan R. L., Lawton, Michael, Rutkowski, Martin, Du, Rose, Lai, Pui Man Rosalind, Patel, Nirav, Frerichs, Kai U.

Mayo Clinic

Journal of Neurosurgery | September 10, 2021 | Volume: 136 | Issue: 4 | Pages: 962-970

10.3171/2021.1.jns202799 | PMID 34608140 Get It

OBJECTIVE The risk-to-benefit profile of treating an unruptured high-grade dural arteriovenous fistula (dAVF) is not clearly defined. The aim of this multicenter retrospective cohort study was to compare the outcomes of different interventions with observation for unruptured high-grade dAVFs. METHODS The authors retrospectively reviewed dAVF patients from 12 institutions participating in the Consortium for Dural Arteriovenous Fistula Outcomes Research (CONDOR). Patients with unruptured high-grade (Borden type II or III) dAVFs were included and categorized into four groups (observation, embolization, surgery, and stereotactic radiosurgery [SRS]) based on the initial management. The primary outcome was defined as the modified Rankin Scale (mRS) score at final follow-up. Secondary outcomes were good outcome (mRS scores 0–2) at final follow-up, symptomatic improvement, all-cause mortality, and dAVF obliteration. The outcomes of each intervention group were compared against those of the observation group as a reference, with adjustment for differences in baseline characteristics. RESULTS The study included 415 dAVF patients, accounting for 29, 324, 43, and 19 in the observation, embolization, surgery, and SRS groups, respectively. The mean radiological and clinical follow-up durations were 21 and 25 months, respectively. Functional outcomes were similar for embolization, surgery, and SRS compared with observation. With observation as a reference, obliteration rates were higher after embolization (adjusted OR [aOR] 7.147, p = 0.010) and surgery (aOR 33.803, p < 0.001) and all-cause mortality was lower after embolization (imputed, aOR 0.171, p = 0.040). Hemorrhage rates per 1000 patient-years were 101 for observation versus 9, 22, and 0 for embolization (p = 0.022), surgery (p = 0.245), and SRS (p = 0.077), respectively. Nonhemorrhagic neurological deficit rates were similar between each intervention group versus observation. CONCLUSIONS Embolization and surgery for unruptured high-grade dAVFs afforded a greater likelihood of obliteration than did observation. Embolization also reduced the risk of death and dAVF-associated hemorrhage compared with conservative management over a modest follow-up period. These findings support embolization as the first-line treatment of choice for appropriately selected unruptured Borden type II and III dAVFs.
Consortium for Dural Arteriovenous Fistula Outcomes Research (CONDOR): rationale, design, and initial characterization of patient cohort
Guniganti, Ridhima, Giordan, Enrico, Chen, Ching-Jen, Abecassis, Isaac Josh, Levitt, Michael R., Durnford, Andrew, Smith, Jessica, Samaniego, Edgar A., Derdeyn, Colin P., Kwasnicki, Amanda, Alaraj, Ali, Potgieser, Adriaan R. E., Sur, Samir, Chen, Stephanie H., Tada, Yoshiteru, Winkler, Ethan, Phelps, Ryan R. L., Lai, Pui Man Rosalind, Du, Rose, Abla, Adib, Satomi, Junichiro, Starke, Robert M., Dijk, J. Marc C. van, Amin-Hanjani, Sepideh, Hayakawa, Minako, Gross, Bradley A., Fox, W. Christopher, Bulters, Diederik, Kim, Louis J., Sheehan, Jason, Lanzino, Giuseppe, Piccirillo, Jay F., Kansagra, Akash P., Zipfel, Gregory J., _, _, _, _, Zipfel, Gregory J., Kansagra, Akash P., Guniganti, Ridhima, Piccirillo, Jay F., Raman, Hari, Lipsey, Kim, Lanzino, Giuseppe, Giordan, Enrico, Brinjikji, Waleed, Vine, Roanna, Cloft, Harry J., Kallmes, David F., Pollock, Bruce E., Link, Michael J., Sheehan, Jason, Chen, Ching-Jen, Patibandla, Mohana Rao, Ding, Dale, Buell, Thomas, Paisan, Gabriella, Kim, Louis J., Levitt, Michael R., Abecassis, Isaac Josh, Meyer, R. Michael, Kelly, Cory, Bulters, Diederik, Durnford, Andrew, Duffill, Jonathan, Ditchfield, Adam, Millar, John, Macdonald, Jason, Fox, W. Christopher, Polifka, Adam J., Laurent, Dimitri, Hoh, Brian, Smith, Jessica, Lockerman, Ashley, Gross, Bradley A., Lunsford, L. Dade, Jankowitz, Brian T., Hayakawa, Minako, Derdeyn, Colin P., Samaniego, Edgar A., Gutierrez, Santiago Ortega, Hasan, David, Roa, Jorge A., Rossen, James, Guerrero, Waldo, McGruder, Allen, Amin-Hanjani, Sepideh, Alaraj, Ali, Kwasnicki, Amanda, Charbel, Fady T., Aletich, Victor A., Rose-Finnell, Linda, Dijk, J. Marc C. van, Potgieser, Adriaan R. E., Starke, Robert M., Peterson, Eric C., Yavagal, Dileep R., Sur, Samir, Chen, Stephanie H., Satomi, Junichiro, Tada, Yoshiteru, Kanematsu, Yasuhisa, Yamamoto, Nobuaki, Kinouchi, Tomoya, Korai, Masaaki, Yamaguchi, Izumi, Yamamoto, Yuki, Abla, Adib, Winkler, Ethan, Phelps, Ryan R. L., Lawton, Michael, Rutkowski, Martin, Du, Rose, Lai, Pui Man Rosalind, Aziz-Sultan, M. Ali, Patel, Nirav, Frerichs, Kai U., Derdeyn, Colin P. , Amin‐Hanjani, Sepideh , Bulters, Diederik , Aziz‐Sultan, Mohammad Ali , Giordan, Enrico , Levitt, Michael R. , Hayakawa, M. , Alaraj, Ali , Dijk, J. Marc C. van , Abla, Adib A. , Smith, Jessica , Korai, Masaaki , Lai, Pui Man Rosalind , Levitt, Michael R , Amin-Hanjani, Sepideh , Alaraj, Ali , van DijK, J Marc C , Abla, Adib , Lai, Rosalind , Bulters, Diederik O , Derdeyn, Colin P , Guniganti, Ridhima, Giordan, Enrico, Chen, Ching-Jen, Abecassis, Isaac Josh, Levitt, Michael R., Durnford, Andrew, Smith, Jessica, Samaniego, Edgar A., Kwasnicki, Amanda, Alaraj, Ali, Potgieser, Adriaan R. E., Sur, Samir, Chen, Stephanie H., Tada, Yoshiteru, Winkler, Ethan, Phelps, Ryan R. L., Lai, Pui Man Rosalind, Du, Rose, Abla, Adib, Satomi, Junichiro, Starke, Robert M., Dijk, J. Marc C. van, Hayakawa, Minako, Gross, Bradley A., Fox, W. Christopher, Kim, Louis J., Sheehan, Jason, Lanzino, Giuseppe, Piccirillo, Jay F., Kansagra, Akash P., Zipfel, Gregory J., _, _, _, _, Zipfel, Gregory J., Kansagra, Akash P., Guniganti, Ridhima, Piccirillo, Jay F., Raman, Hari, Lipsey, Kim, Lanzino, Giuseppe, Brinjikji, Waleed, Vine, Roanna, Cloft, Harry J., Kallmes, David F., Pollock, Bruce E., Link, Michael J., Sheehan, Jason, Chen, Ching-Jen, Patibandla, Mohana Rao, Ding, Dale, Buell, Thomas, Paisan, Gabriella, Kim, Louis J., Abecassis, Isaac Josh, Meyer, R. Michael, Kelly, Cory, Bulters, Diederik, Durnford, Andrew, Duffill, Jonathan, Ditchfield, Adam, Millar, John, Macdonald, Jason, Fox, W. Christopher, Polifka, Adam J., Laurent, Dimitri, Hoh, Brian, Smith, Jessica, Lockerman, Ashley, Gross, Bradley A., Lunsford, L. Dade, Jankowitz, Brian T., Hayakawa, Minako, Derdeyn, Colin P., Samaniego, Edgar A., Gutierrez, Santiago Ortega, Hasan, David, Roa, Jorge A., Rossen, James, Guerrero, Waldo, McGruder, Allen, Amin-Hanjani, Sepideh, Kwasnicki, Amanda, Charbel, Fady T., Aletich, Victor A., Rose-Finnell, Linda, Dijk, J. Marc C. van, Potgieser, Adriaan R. E., Starke, Robert M., Peterson, Eric C., Yavagal, Dileep R., Sur, Samir, Chen, Stephanie H., Satomi, Junichiro, Tada, Yoshiteru, Kanematsu, Yasuhisa, Yamamoto, Nobuaki, Kinouchi, Tomoya, Yamaguchi, Izumi, Yamamoto, Yuki, Winkler, Ethan, Phelps, Ryan R. L., Lawton, Michael, Rutkowski, Martin, Du, Rose, Lai, Pui Man Rosalind, Patel, Nirav, Frerichs, Kai U.

Mayo Clinic

Journal of Neurosurgery | September 10, 2021 | Volume: 136 | Issue: 4 | Pages: 951-961

10.3171/2021.1.jns202790 | PMID 34507282 Get It

OBJECTIVE Cranial dural arteriovenous fistulas (dAVFs) are rare lesions, hampering efforts to understand them and improve their care. To address this challenge, investigators with an established record of dAVF investigation formed an international, multicenter consortium aimed at better elucidating dAVF pathophysiology, imaging characteristics, natural history, and patient outcomes. This report describes the design of the Consortium for Dural Arteriovenous Fistula Outcomes Research (CONDOR) and includes characterization of the 1077-patient cohort. METHODS Potential collaborators with established interest in the field were identified via systematic review of the literature. To ensure uniformity of data collection, a quality control process was instituted. Data were retrospectively obtained. RESULTS CONDOR comprises 14 centers in the United States, the United Kingdom, the Netherlands, and Japan that have pooled their data from 1077 dAVF patients seen between 1990 and 2017. The cohort includes 359 patients (33%) with Borden type I dAVFs, 175 (16%) with Borden type II fistulas, and 529 (49%) with Borden type III fistulas. Overall, 852 patients (79%) presented with fistula-related symptoms: 427 (40%) presented with nonaggressive symptoms such as tinnitus or orbital phenomena, 258 (24%) presented with intracranial hemorrhage, and 167 (16%) presented with nonhemorrhagic neurological deficits. A smaller proportion (224 patients, 21%), whose dAVFs were discovered incidentally, were asymptomatic. Many patients (85%, 911/1077) underwent treatment via endovascular embolization (55%, 587/1077), surgery (10%, 103/1077), radiosurgery (3%, 36/1077), or multimodal therapy (17%, 184/1077). The overall angiographic cure rate was 83% (758/911 treated), and treatment-related permanent neurological morbidity was 2% (27/1467 total procedures). The median time from diagnosis to follow-up was 380 days (IQR 120–1038.5 days). CONCLUSIONS With more than 1000 patients, the CONDOR registry represents the largest registry of cranial dAVF patient data in the world. These unique, well-annotated data will enable multiple future analyses to be performed to better understand dAVFs and their management.
Recurrence after cure in cranial dural arteriovenous fistulas: a collaborative effort by the Consortium for Dural Arteriovenous Fistula Outcomes Research (CONDOR)
Abecassis, Isaac Josh, Meyer, R. Michael, Levitt, Michael R., Sheehan, Jason P., Chen, Ching-Jen, Gross, Bradley A., Smith, Jessica, Fox, W. Christopher, Giordan, Enrico, Lanzino, Giuseppe, Starke, Robert M., Sur, Samir, Potgieser, Adriaan R. E., Dijk, J. Marc C. van, Durnford, Andrew, Bulters, Diederik, Satomi, Junichiro, Tada, Yoshiteru, Kwasnicki, Amanda, Amin-Hanjani, Sepideh, Alaraj, Ali, Samaniego, Edgar A., Hayakawa, Minako, Derdeyn, Colin P., Winkler, Ethan, Abla, Adib, Lai, Pui Man Rosalind, Du, Rose, Guniganti, Ridhima, Kansagra, Akash P., Zipfel, Gregory J., Kim, Louis J., _, _, _, _, Zipfel, Gregory J., Kansagra, Akash P., Guniganti, Ridhima, Piccirillo, Jay F., Raman, Hari, Lipsey, Kim, Lanzino, Giuseppe, Giordan, Enrico, Brinjikji, Waleed, Vine, Roanna, Cloft, Harry J., Kallmes, David F., Pollock, Bruce E., Link, Michael J., Sheehan, Jason, Chen, Ching-Jen, Patibandla, Mohana Rao, Ding, Dale, Buell, Thomas, Paisan, Gabriella, Kim, Louis J., Levitt, Michael R., Abecassis, Isaac Josh, Meyer, R. Michael, Kelly, Cory, Bulters, Diederik, Durnford, Andrew, Duffill, Jonathan, Ditchfield, Adam, Millar, John, Macdonald, Jason, Fox, W. Christopher, Polifka, Adam J., Laurent, Dimitri, Hoh, Brian, Smith, Jessica, Lockerman, Ashley, Gross, Bradley A., Lunsford, L. Dade, Jankowitz, Brian T., Hayakawa, Minako, Derdeyn, Colin P., Samaniego, Edgar A., Gutierrez, Santiago Ortega, Hasan, David, Roa, Jorge A., Rossen, James, Guerrero, Waldo, McGruder, Allen, Amin-Hanjani, Sepideh, Alaraj, Ali, Kwasnicki, Amanda, Charbel, Fady T., Aletich, Victor A., Rose-Finnell, Linda, Dijk, J. Marc C. van, Potgieser, Adriaan R. E., Starke, Robert M., Peterson, Eric C., Yavagal, Dileep R., Sur, Samir, Chen, Stephanie H., Satomi, Junichiro, Tada, Yoshiteru, Kanematsu, Yasuhisa, Yamamoto, Nobuaki, Kinouchi, Tomoya, Korai, Masaaki, Yamaguchi, Izumi, Yamamoto, Yuki, Abla, Adib, Winkler, Ethan, Phelps, Ryan R. L., Lawton, Michael, Rutkowski, Martin, Du, Rose, Lai, Pui Man Rosalind, Aziz-Sultan, M. Ali, Patel, Nirav, Frerichs, Kai U., Derdeyn, Colin P. , Amin‐Hanjani, Sepideh , Bulters, Diederik , Aziz‐Sultan, Mohammad Ali , Giordan, Enrico , Levitt, Michael R. , Hayakawa, M. , Alaraj, Ali , Dijk, J. Marc C. van , Abla, Adib A. , Korai, Masaaki , Levitt, Michael R , Amin-Hanjani, Sepideh , Alaraj, Ali , van DijK, J Marc C , Abla, Adib , Bulters, Diederik O , Derdeyn, Colin P , Abecassis, Isaac Josh, Meyer, R. Michael, Sheehan, Jason P., Chen, Ching-Jen, Gross, Bradley A., Smith, Jessica, Fox, W. Christopher, Giordan, Enrico, Lanzino, Giuseppe, Starke, Robert M., Sur, Samir, Potgieser, Adriaan R. E., Dijk, J. Marc C. van, Durnford, Andrew, Satomi, Junichiro, Tada, Yoshiteru, Kwasnicki, Amanda, Samaniego, Edgar A., Hayakawa, Minako, Derdeyn, Colin P., Winkler, Ethan, Lai, Pui Man Rosalind, Du, Rose, Guniganti, Ridhima, Kansagra, Akash P., Zipfel, Gregory J., Kim, Louis J., _, _, _, _, Zipfel, Gregory J., Kansagra, Akash P., Guniganti, Ridhima, Piccirillo, Jay F., Raman, Hari, Lipsey, Kim, Lanzino, Giuseppe, Brinjikji, Waleed, Vine, Roanna, Cloft, Harry J., Kallmes, David F., Pollock, Bruce E., Link, Michael J., Sheehan, Jason, Chen, Ching-Jen, Patibandla, Mohana Rao, Ding, Dale, Buell, Thomas, Paisan, Gabriella, Kim, Louis J., Levitt, Michael R., Abecassis, Isaac Josh, Meyer, R. Michael, Kelly, Cory, Bulters, Diederik, Durnford, Andrew, Duffill, Jonathan, Ditchfield, Adam, Millar, John, Macdonald, Jason, Fox, W. Christopher, Polifka, Adam J., Laurent, Dimitri, Hoh, Brian, Smith, Jessica, Lockerman, Ashley, Gross, Bradley A., Lunsford, L. Dade, Jankowitz, Brian T., Hayakawa, Minako, Samaniego, Edgar A., Gutierrez, Santiago Ortega, Hasan, David, Roa, Jorge A., Rossen, James, Guerrero, Waldo, McGruder, Allen, Amin-Hanjani, Sepideh, Alaraj, Ali, Kwasnicki, Amanda, Charbel, Fady T., Aletich, Victor A., Rose-Finnell, Linda, Dijk, J. Marc C. van, Potgieser, Adriaan R. E., Starke, Robert M., Peterson, Eric C., Yavagal, Dileep R., Sur, Samir, Chen, Stephanie H., Satomi, Junichiro, Tada, Yoshiteru, Kanematsu, Yasuhisa, Yamamoto, Nobuaki, Kinouchi, Tomoya, Yamaguchi, Izumi, Yamamoto, Yuki, Abla, Adib, Winkler, Ethan, Phelps, Ryan R. L., Lawton, Michael, Rutkowski, Martin, Du, Rose, Lai, Pui Man Rosalind, Patel, Nirav, Frerichs, Kai U.

Mayo Clinic

Journal of Neurosurgery | September 10, 2021 | Volume: 136 | Issue: 4 | Pages: 981-989

10.3171/2021.1.jns202033 | PMID 34507283 Get It

OBJECTIVE Cranial dural arteriovenous fistulas (dAVFs) are often treated with endovascular therapy, but occasionally a multimodality approach including surgery and/or radiosurgery is utilized. Recurrence after an initial angiographic cure has been reported, with estimated rates ranging from 2% to 14.3%, but few risk factors have been identified. The objective of this study was to identify risk factors associated with recurrence of dAVF after putative cure. METHODS The Consortium for Dural Arteriovenous Fistula Outcomes Research (CONDOR) data were retrospectively reviewed. All patients with angiographic cure after treatment and subsequent angiographic follow-up were included. The primary outcome was recurrence, with risk factor analysis. Secondary outcomes included clinical outcomes, morbidity, and mortality associated with recurrence. Risk factor analysis was performed comparing the group of patients who experienced recurrence with those with durable cure (regardless of multiple recurrences). Time-to-event analysis was performed using all collective recurrence events (multiple per patients in some cases). RESULTS Of the 1077 patients included in the primary CONDOR data set, 457 met inclusion criteria. A total of 32 patients (7%) experienced 34 events of recurrence at a mean of 368.7 days (median 192 days). The recurrence rate was 4.5% overall. Kaplan-Meier analysis predicted long-term recurrence rates approaching 11% at 3 years. Grade III dAVFs treated with endovascular therapy were statistically significantly more likely to experience recurrence than those treated surgically (13.3% vs 0%, p = 0.0001). Tentorial location, cortical venous drainage, and deep cerebral venous drainage were all risk factors for recurrence. Endovascular intervention and radiosurgery were associated with recurrence. Six recurrences were symptomatic, including 2 with hemorrhage, 3 with nonhemorrhagic neurological deficit, and 1 with progressive flow-related symptoms (decreased vision). CONCLUSIONS Recurrence of dAVFs after putative cure can occur after endovascular treatment. Risk factors include tentorial location, cortical venous drainage, and deep cerebral drainage. Multimodality therapy can be used to achieve cure after recurrence. A delayed long-term angiographic evaluation (at least 1 year from cure) may be warranted, especially in cases with risk factors for recurrence.
Machine learning approach to differentiation of peripheral schwannomas and neurofibromas: A multi-center study
Zhang, Michael , Tong, Elizabeth , Wong, Sam, Hamrick, Forrest , Mohammadzadeh, Maryam , Rao, Vaishnavi , Pendleton, Courtney , Hug, Nicholas F. , Biswal, Sandip , Seekins, Jayne , Napel, Sandy , Spinner, Robert J. , Yeom, Kristen W. , Wilson, Thomas J. , Wilson, Thomas J , Rao, Vaishnavi L , Smith, Brandon W. , Mahan, Mark A

Mayo Clinic

Neuro-Oncology | September 6, 2021 | Volume: 24 | Issue: 4 | Pages: 601-609

10.1093/neuonc/noab211 | PMID 34487172 Get It

Abstract Background Non-invasive differentiation between schwannomas and neurofibromas is important for appropriate management, preoperative counseling, and surgical planning, but has proven difficult using conventional imaging. The objective of this study was to develop and evaluate machine learning approaches for differentiating peripheral schwannomas from neurofibromas. Methods We assembled a cohort of schwannomas and neurofibromas from 3 independent institutions and extracted high-dimensional radiomic features from gadolinium-enhanced, T1-weighted MRI using the PyRadiomics package on Quantitative Imaging Feature Pipeline. Age, sex, neurogenetic syndrome, spontaneous pain, and motor deficit were recorded. We evaluated the performance of 6 radiomics-based classifier models with and without clinical features and compared model performance against human expert evaluators. Results One hundred and seven schwannomas and 59 neurofibromas were included. The primary models included both clinical and imaging data. The accuracy of the human evaluators (0.765) did not significantly exceed the no-information rate (NIR), whereas the Support Vector Machine (0.929), Logistic Regression (0.929), and Random Forest (0.905) classifiers exceeded the NIR. Using the method of DeLong, the AUCs for the Logistic Regression (AUC = 0.923) and K Nearest Neighbor (AUC = 0.923) classifiers were significantly greater than the human evaluators (AUC = 0.766; p = 0.041). Conclusions The radiomics-based classifiers developed here proved to be more accurate and had a higher AUC on the ROC curve than expert human evaluators. This demonstrates that radiomics using routine MRI sequences and clinical features can aid in differentiation of peripheral schwannomas and neurofibromas.
Epigenomic features related to microglia are associated with attenuated effect of APOE ε4 on Alzheimer's disease risk in humans
Yu, Lei , Olah, Marta , Smith, Rebecca G. , Oatman, Stephanie R., Allen, Mariet , Pishva, Ehsan , Zhang, Bin , Ertekin‐Taner, Nilüfer , Bennett, David A. , Klein, Hans‐Ulrich , Jager, Philip L. De , Bennett, David A. , Ma, Yiyi , Menon, Vilas , Lunnon, Katie

Mayo Clinic

Alzheimer's & Dementia | September 5, 2021 | Volume: 18 | Issue: 4 | Pages: 688-699

10.1002/alz.12425 | PMID 34482628 Get It

Abstract Not all apolipoprotein E ( APOE ) ε4 carriers who survive to advanced age develop Alzheimer's disease (AD); factors attenuating the risk of ε4 on AD may exist. Guided by the top ε4‐attenuating signals from methylome‐wide association analyses (N = 572, ε4+ and ε4–) of neurofibrillary tangles and neuritic plaques, we conducted a meta‐analysis for pathological AD within the ε4+ subgroups (N = 235) across four independent collections of brains. Cortical RNA‐seq and microglial morphology measurements were used in functional analyses. Three out of the four significant CpG dinucleotides were captured by one principal component (PC1), which interacts with ε4 on AD, and is associated with expression of innate immune genes and activated microglia. In ε4 carriers, reduction in each unit of PC1 attenuated the odds of AD by 58% (odds ratio = 2.39, 95% confidence interval = [1.64,3.46], P = 7.08 × 10 –6 ). An epigenomic factor associated with a reduced proportion of activated microglia (epigenomic factor of activated microglia, EFAM) appears to attenuate the risk of ε4 on AD.